| Literature DB >> 34295836 |
Renata S Auriemma1, Roberta Scairati1, Guendalina Del Vecchio1, Alessia Liccardi1, Nunzia Verde1, Rosa Pirchio1, Rosario Pivonello1, Danilo Ercolini2, Annamaria Colao1,3.
Abstract
Vaginal microbial niche is a dynamic ecosystem, composed by more than 200 bacterial species which are influenced by genes, ethnic background and environmental-behavioral factors. Several lines of evidence have well documented that vaginal microbiome constantly changes over the course of woman's life, so to exert an important impact on woman quality of life, from newborn to post-menopausal ages. This review aims at analyzing the role of vaginal microbiome in the maintenance of woman's homeostasis and at tracking critical changes that commonly occur across woman's lifetime. The role of hormone replacement therapy in the modulation of vaginal microbiome composition and in the improvement of vaginal wellness in postmenopausal women with decreasing levels of circulating estrogen is discussed.Entities:
Keywords: bacterial vaginosis; estrogen and progestin variations; vaginal microbiome; woman health; woman homeostasis
Year: 2021 PMID: 34295836 PMCID: PMC8290858 DOI: 10.3389/fcimb.2021.686167
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Changes in the composition of vaginal microbiome throughout women life. In childhood (left panel), Corynebacterium spp., coagulase-negative Staphylococcus spp., Escherichia coli and Mycoplasma spp., form the vaginal microbiome. At puberty, upon estrogen/progestin exposure the vaginal microbial niche shifts towards other predominant colonies, mainly including Lactobacillus spp., Atopobium, and Streptococcus spp. During reproductive age (middle panel), vaginal microbiome houses a range of bacterial communities, mainly including lactobacilli (L. crispatus, L. gasseri, L. jensenii and L. iners) along with anaerobic bacteria. Menopause (right panel) induces further changes in the composition of vaginal microbiome, mainly composed by Gardnerella vaginalis, Ureaplasma urealyticum, Candida albicans and Prevotella spp., together with a progressive decrease in species of Lactobacillus. Created with BioRender.com.
Effects of probiotics supplementation in non-pregnant women affected by vulvo-vaginal candidiasis.
| List of research studies included in the Cochrane metanalysis on the usage of probiotics added to antifungals for the treatment of vulvo-vaginal candidiasis (patient cohort = 1656 women) | |||
|---|---|---|---|
| Study | Therapeutic regimen | Route of probiotics administration | Endpoints |
|
| L. delbrueckii subsp. Lactis DM8909 + Miconazole | Vaginal |
Long-term clinical and mycological cure rates (assessed at 1 and 3 months after completion of the treatment); Rate of adverse events. |
|
| L. delbrueckii subsp. Lactis DM8909 + Clotrimazole | Vaginal |
Short-term clinical and mycological cure rates (assessed at 7-10 days after completion of treatment); First relapse after treatment (1 month after completion of treatment); Rate of adverse events. |
|
| L. delbrueckii subsp. Lactis DM8909 + Clotrimazole | Vaginal |
Short-term mycological cure rate (7 days after completion of treatment); Rate of adverse events. |
|
| L. delbrueckii subsp. Lactis DM8909 + Miconazole | Vaginal |
Short-term clinical and mycological cure rate (5-7 days after completion of treatment); First relapse after treatment (33-37 days after completion of treatment) |
|
| L. delbrueckii subsp. Lactis DM8909 + Clotrimazole | Vaginal |
Short-term clinical and mycological cure rate (7-10 days after completion of treatment); First relapse after treatment (1 month after completion of treatment); Rate of adverse events. |
|
| Streptococcus faecalis + Miconazole | Vaginal |
Short-term clinical and mycological cure rate (7 days after completion of treatment); Rate of adverse events. |
|
| Streptococcus faecalis + Clotrimazole | Vaginal |
Short-term mycological cure rate (7 days after completion of treatment); Rate of adverse events. |
|
| L. rhamnosus GR-1 and L. reuteri RC-14 + Fluconazole | Oral |
Long-term mycological cure rate (28 days after beginning of treatment). |
|
| L. casei, L. rhamnosus, S. thermophilus, Bifidobacterium breve, L. acidophilus, Bifidobacterium longum and L. bulgaricus + Fluconazole | Oral |
Short-term clinical cure rate; Short-term mycological cure rate. |
|
| L. acidophilus, L. rhamnosus, S. thermophilus and L. delbrueckii subsp. Bulgaricus + Fluconazole plus Fenticonazole | Fluconazole: oral Fenticonazole: vaginal Probiotics: vaginal |
Long-term mycological cure rate (28 days after beginning of treatment) |
Adapted from reference (Pasolli et al., 2020).
Effects of probiotics supplementation in non-pregnant women affected by bacterial vaginosis.
| List of research studies included in the Huang metanalysis on the usage of probiotics alone or as adjuvants against bacterial vaginosis (patient cohort = 1304 women) | |||
|---|---|---|---|
| Study | Therapeutic regimen | Route of probiotics administration | Risk Ratio [95% confidence interval (CI)] of the proposed therapeutic regimen compared to placebo |
|
| L. acidophilus | Vaginal | 34.14 [2.15, 543.06] |
|
| Hydrogen peroxide-producing strain of L. acidophilus + Estriol | Vaginal | 3.50 [1.47, 8.34] |
|
| L. gasseri, L. casei rhamnosus, L. fermentum + Clindamycin | Vaginal | 0.90 [0.71, 1.14] |
|
| L. rhamnosus gR-1 and L. reuteri RC-14 + Metronidazole | Oral | 2.19 [1.59, 3.03] |
|
| L. casei rhamnosus (Lcr35), lactose, and magnesium stearate + antibiotic treatment | Vaginal | 2.32 [1.75, 3.09] |
|
| Freeze-dried L. rhamnosus + Metronidazole | Vaginal | 1.09 [0.91, 1.31] |
|
| Freeze-dried lactobacilli + Clindamycin cream | Vaginal | 1.43 [1.00, 2.06] |
|
| L. brevis CD2, L. salivarius FV2, and L. plantarum FV9 | Vaginal | 8.00 [1.13, 56,41] |
|
| L. rhamnosus GR-1 and L. reuteri RC + Tinidazole | Vaginal | 1.75 [1.21, 2.53] |
|
| Lactobacillus rhamnosus, L acidophilus, and Streptococcus thermophilus | Vaginal | 1.53 [1.19, 1.98] |
|
| L. rhamnosus + Metronidazole | Vaginal | 1.24 [0.94, 1.62] |
|
| L. acidophilus KS400, Estriol + Metronidazole | Vaginal | 0.95 [0.82, 1.11] |
|
| |||
Adapted from reference (Bakken, 1985).